drugset / Trial / NCT03239691

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

NCT03239691 ↗

Phase 2 Completed 5 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedSingle-groupSingle-blindOther

Summary

The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration

Timeline

Start
2017-10-06
Primary completion
2018-04-25
Completion
2018-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject APINOCALTAMIDE Small molecule 10 mg Oral
Subject APINOCALTAMIDE Small molecule 100 mg Oral